Phospholipase C inhibitors for use in treating inflammatory disorders
US7262197B2 · kind B2 · utility
3Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2004 |
| Grant date | Aug 28, 2007 |
| Priority date | — |
| Expiry date | Mar 25, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/192
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention is directed to heterocyclyl-substituted anilino phospholipase C inhibitor compounds useful in treating or ameliorating an inflammatory disorders and/or restenosis of the general formula (I):and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions affected by phospholipase modulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.